0001209191-20-064531.txt : 20201218 0001209191-20-064531.hdr.sgml : 20201218 20201218191823 ACCESSION NUMBER: 0001209191-20-064531 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201217 FILED AS OF DATE: 20201218 DATE AS OF CHANGE: 20201218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ramasastry Saira CENTRAL INDEX KEY: 0001547959 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 201401999 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-17 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001547959 Ramasastry Saira C/O SANGAMO THERAPEAUTICS, INC. 7000 MARINA BLVD BRISBANE CA 94405 1 0 0 0 Common Stock 2020-12-17 4 M 0 10000 5.99 A 25000 D Common Stock 2020-12-17 4 S 0 10000 13.2747 D 15000 D Stock Option (Right-to-Buy) 5.99 2020-12-17 4 M 0 10000 0.00 D 2026-06-13 Common Stock 10000 0 D Includes 10,000 shares of common stock subject to restricted stock units ("RSUs") granted on May 15, 2020. The RSUs will fully vest on the earlier of (x) May 15, 2021 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service through such dates as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended") and subject to acceleration as defined in the 2018 EIP, as amended. The price reported is a weighted average price. The shares were sold at prices ranging from $13.26 to $13.32 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant. /s/ Matthew Colvin, Attorney-in-Fact for Saira Ramasastry 2020-12-18